Skip to content

A Randomized Controlled Trial Comparing the Efficacy of Tuina Therapy versus Pharmacological Intervention in Knee Osteoarthritis

A Randomized Controlled Trial Comparing the Efficacy of Tuina Therapy versus Pharmacological Intervention in Knee Osteoarthritis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000961
Enrollment
Unknown
Registered
2025-05-13
Start date
2025-03-28
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Interventions

Treatment group:Tuina Therapy
Control group:Diclofenac Sodium Transdermal Patch

Sponsors

Shanghai Municipal Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Meeting the above diagnostic criteria for knee osteoarthritis or having been clinically diagnosed with KOA; 2) Meeting the Kellgren-Lawrence (K-L) classification of grade I-III on standing knee X-ray films: Grade I: Suspected narrowing of the knee joint space with possible minor osteophytes (bony protrusions at the edge of the knee joint); Grade II: Clear presence of small osteophytes with suspected narrowing of the joint space; Grade III: Presence of moderate osteophytes with clear narrowing of the joint space and sclerotic changes; 3) Numerical Rating Scale (NRS) score of 3 or above (on a scale of 0-10); 4) Age between 40 and 80 years old with no gender restrictions; 5) Voluntary participation in this trial and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1) History of knee trauma and surgery; 2) Other knee treatment history in the past 6 months; 3) Knee joint diseases such as tumors tuberculosis osteomyelitis etc.; 4) Severe liver and kidney dysfunction severe cardiovascular disease diabetes mental illness; 5) Rheumatoid arthritis fibromyalgia or other systemic rheumatic immune diseases; 6) Total knee replacement or other major lower extremity surgeries in the past 6 months or planned within the next 9 months; 7) Severe hearing or vision impairment; 8) History of allergy to non-steroidal anti-inflammatory drugs; 9) Alcohol abuse and drug abuse; 10) Currently participating in another clinical study.

Design outcomes

Primary

MeasureTime frame
The changes in WOMAC pain scale values after 4 weeks of treatment;

Secondary

MeasureTime frame
MyotonPRO;Timed Up and Go test;Short Physical Performance Battery;Short Form-36 Health Survey;the Western Ontario and McMaster Universities Osteoarthritis Index;

Countries

China

Contacts

Public ContactYAO Fei

Shanghai Municipal Hospital of Traditional Chinese Medicine

doctoryaofei@shutcm.edu.cn13585975106

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026